L

LegoChem Biosciences Inc
KOSDAQ:141080

Watchlist Manager
LegoChem Biosciences Inc
KOSDAQ:141080
Watchlist
Price: 103 300 KRW 6.17% Market Closed
Market Cap: 3.8T KRW
Have any thoughts about
LegoChem Biosciences Inc?
Write Note

LegoChem Biosciences Inc
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

LegoChem Biosciences Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
L
LegoChem Biosciences Inc
KOSDAQ:141080
Net Income (Common)
-â‚©2.9B
CAGR 3-Years
58%
CAGR 5-Years
-22%
CAGR 10-Years
9%
Samsung Biologics Co Ltd
KRX:207940
Net Income (Common)
â‚©1.1T
CAGR 3-Years
37%
CAGR 5-Years
27%
CAGR 10-Years
N/A
K
Knotus Co Ltd
KOSDAQ:278650
Net Income (Common)
-â‚©164m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
ST Pharm Co Ltd
KOSDAQ:237690
Net Income (Common)
â‚©32.4B
CAGR 3-Years
104%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
F
FutureChem Co Ltd
KOSDAQ:220100
Net Income (Common)
-â‚©10.6B
CAGR 3-Years
13%
CAGR 5-Years
1%
CAGR 10-Years
N/A
C
Cellivery Therapeutics Inc
KOSDAQ:268600
Net Income (Common)
-â‚©6.1B
CAGR 3-Years
37%
CAGR 5-Years
21%
CAGR 10-Years
N/A
No Stocks Found

LegoChem Biosciences Inc
Glance View

Market Cap
3.8T KRW
Industry
Life Sciences Tools & Services

LegoChem Biosciences Inc., rooted in South Korea, is navigating the complex world of pharmaceutical innovation with a focus sharp enough to captivate both scientists and investors. Founded in 2006, the company has honed its expertise particularly in the field of antibody-drug conjugates (ADCs). This novel approach merges the targeting capabilities of antibodies with the cancer-killing prowess of chemotherapy drugs, aiming to deliver high precision in cancer treatment while minimizing side effects. LegoChem conducts meticulous research and development, advancing its proprietary ConjuAll™ technology platform, which enhances the stability and efficacy of ADCs. This dedication to scientific innovation underscores the company's strategy of robust collaboration and partnerships with global pharmaceutical giants, enabling it to leverage complementary expertise and expedite the commercialization of its cutting-edge therapies. LegoChem Biosciences generates revenue primarily through a strategic business model that revolves around licensing agreements and research collaborations with major pharmaceutical players. The company enters into partnerships where it licenses out its advanced drug discovery platforms, receiving upfront payments, milestones based on developmental progress, and royalties upon successful commercialization of its licensed products. These collaborative strategies not only finance ongoing research but also diversify revenue streams and mitigate the inherent financial risks associated with drug development. By focusing on areas with high unmet medical needs, LegoChem not only positions itself advantageously in the competitive biotech landscape but also aligns with a mission to transform lives through innovation. With a clear-eyed vision and strategic partnerships, LegoChem Biosciences Inc. continues its quest to make significant strides in the realm of targeted cancer therapies.

Intrinsic Value
25 744.73 KRW
Overvaluation 75%
Intrinsic Value
Price
L

See Also

What is LegoChem Biosciences Inc's Net Income (Common)?
Net Income (Common)
-2.9B KRW

Based on the financial report for Sep 30, 2024, LegoChem Biosciences Inc's Net Income (Common) amounts to -2.9B KRW.

What is LegoChem Biosciences Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
9%

Over the last year, the Net Income (Common) growth was 96%. The average annual Net Income (Common) growth rates for LegoChem Biosciences Inc have been 58% over the past three years , -22% over the past five years , and 9% over the past ten years .

Back to Top